SCHEMBL4494162

SCHEMBL4494162

CN1CCN(CC(=O)Nc2ccc(NC(=C3C(=O)Nc4cc(Cl)ccc43)c3ccccc3)cc2F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ POLB P06746 3/20 0.48
▸ NPC1 O15118 1/20 0.46
▸ LMNA P02545 3/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ ABCB1 P08183 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ FLT3 P36888 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494155 1.00 SMN1; SMN2 (0.55) SMN1; SMN2POLBNPC1LMNAL3MBTL1
SCHEMBL4480613 0.92 SMN1; SMN2 (0.55) SMN1; SMN2POLBLMNAL3MBTL1HTT
SCHEMBL4480609 0.92 SMN1; SMN2 (0.55) SMN1; SMN2POLBLMNAL3MBTL1HTT
SCHEMBL4504513 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAABCB1KDM4E
SCHEMBL4504518 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAABCB1KDM4E
SCHEMBL4488669 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAL3MBTL1HTT
SCHEMBL4503948 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAL3MBTL1HTT
SCHEMBL4493467 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAHTTABCB1
SCHEMBL4488674 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAL3MBTL1HTT
SCHEMBL4493472 0.92 SMN1; SMN2 (0.56) SMN1; SMN2POLBLMNAHTTABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 — — US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR SMN1; SMN2 4006/4885POLB 4146/4885NPC1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback